MedTrace Logo

Pharmacokinetic Interaction Between BIA 9-1067 and Standard-release Levodopa/Carbidopa

NCT01533077 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2015-12-22

Study results available
· View outcomes & findings →

Summary

To investigate the pharmacokinetics of levodopa when administered concomitantly with BIA 9-1067 or 1 hour after.

Conditions

  • Parkinson Disease

Interventions

DRUG

BIA 9-1067

50 mg of BIA 9-1067 (single-dose)

DRUG

Sinemet® 100/25 mg

immediate-release levodopa/carbidopa 100/25 (single-dose).

Sponsors & Collaborators

  • Bial - Portela C S.A.

    lead INDUSTRY

Principal Investigators

  • Eric Sicard, MD · Algorithme Pharma Inc

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-03-31
Primary Completion
2009-10-31
Completion
2010-02-28

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01533077 on ClinicalTrials.gov